SynthesisEmerging microbes & infections2026
High pathogenicity of human adenovirus type 55 in adult males: a meta-analysis and phylogenetic study of HAdV-55 epidemics worldwide over the past six decades.
Synthesis in Emerging microbes & infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Human adenovirus type 55 (HAdV-55), formerly designated as HAdV-11a, is a notable recombinant pathogen linked to severe respiratory infections. Since its reclassification as HAdV-55 in 2010, numerous outbreaks of pneumonia associated with it have been documented over the past decade. We conducted a systematic review of 111 peer-reviewed articles from PubMed, Web of Science, and China National Knowledge Infrastructure (CNKI) spanning the 60 years (1965-2024). Furthermore, we performed phylogenetic analysis on 87 complete HAdV-55 genomes available in GenBank. Bayesian methods were employed to estimate the temporal evolutionary dynamics of HAdV-55. A total of 15,245 HAdV-55 cases were identified, including 3,790 pneumonia cases (24.86%) and 33 fatalities (case fatality rate: 0.22%), of which 21 (63.63%) were male and the remainder unspecified. Military recruits comprised 79.06% of the cases (12,039/15,245), with adults (95.39%) and males (97.61%) predominantly affected. Asia accounted for the majority of cases (15,060, 98.79%), primarily in China (89.90%), followed by North America (0.98%). The infections caused by HAdV-55 are associated with respiratory (87.27%), gastrointestinal (2.71%), ocular (0.30%), and mental (0.07%) disorders. Phylogenetic analysis identified four variants: HAdV-55a through HAdV-55d, with HAdV-55d emerging as the dominant circulating strain since 2006. Additionally, the E3 region harbours distinct amino acid substitutions correlated with specific countries, suggesting evolution for immune evasion. Bayesian evolutionary analysis estimated the most recent common ancestor (tMRCA) originated in 1929 (95% HPD: 1890-1967). This study underscores the high prevalence of HAdV-55 among adults and males, particularly in China, highlighting the urgent necessity for antiviral therapeutics and vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.